1. A susceptibility biomarker identification strategy based on significantly differentially expressed ceRNA triplets for ischemic cardiomyopathy
- Author
-
Erqiang Hu, Benliang Wei, Gui Deng, Yahui Wang, Zherou Rong, Yuqing Zou, Wenshuai Li, Zhaona Song, Yang Liu, Yuehan He, Junjie Lv, Wan Li, and Lina Chen
- Subjects
0301 basic medicine ,Biomarker identification ,Bioinformatics ,mRNA ,Biophysics ,Computational biology ,Disease ,Biology ,Biochemistry ,03 medical and health sciences ,lncRNA ,0302 clinical medicine ,microRNA ,Humans ,Gene Regulatory Networks ,Systems Biology & Networks ,Molecular Biology ,Gene ,Diagnostics & Biomarkers ,Research Articles ,reproductive and urinary physiology ,miRNA ,Messenger RNA ,Ischemic cardiomyopathy ,Competing endogenous RNA ,Computational Biology ,Human heart ,Genomics ,ceRNA ,Cell Biology ,equipment and supplies ,ICM ,030104 developmental biology ,030220 oncology & carcinogenesis ,embryonic structures ,RNA ,Cardiomyopathies ,Biomarkers ,circulatory and respiratory physiology - Abstract
Ischemic cardiomyopathy (ICM) is a common human heart disease that causes death. No effective biomarkers for ICM could be found in existing databases, which is detrimental to the in-depth study of this disease. In the present study, ICM susceptibility biomarkers were identified using a proposed strategy based on RNA-Seq and miRNA-Seq data of ICM and normal samples. Significantly differentially expressed competing endogenous RNA (ceRNA) triplets were constructed using permutation tests and differentially expressed mRNAs, miRNAs and lncRNAs. Candidate ICM susceptible genes were screened out as differentially expressed genes in significantly differentially expressed ceRNA triplets enriched in ICM-related functional classes. Finally, eight ICM susceptibility genes and their significantly correlated lncRNAs with high classification accuracy were identified as ICM susceptibility biomarkers. These biomarkers would contribute to the diagnosis and treatment of ICM. The proposed strategy could be extended to other complex diseases without disease biomarkers in public databases.
- Published
- 2020
- Full Text
- View/download PDF